This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Higher for Longer: 3 Stocks to Benefit from Falling Rate Cut Expectations
by Ethan Feller
With a robust labor market and higher than expected inflation, we can expect rates to stay high for at least a few more months
Are Investors Undervaluing HCA Healthcare (HCA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Momentum Monday: Inflation Data, Earnings, and Semiconductors
by Ethan Feller
Want to start the week ahead of the pack? Check out Momentum Mondays
5 Must-Buy S&P 500 Stocks as Index Crosses Key Milestone
by Nalak Das
We have narrowed our search to five U.S. corporate behemoths in the S&P stable. These are: AMZN, META, NFLX, PGR, HCA.
Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down
by Zacks Equity Research
Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.
Haemonetics (HAE) Q3 Earnings Top Estimates, 2024 View Raised
by Zacks Equity Research
Haemonetics' (HAE) proprietary technology, Persona, continues to gain momentum in the third quarter.
Why HCA Healthcare (HCA) is a Top Stock for the Long-Term
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
3 Medical Stocks to Buy as the Sector Continues to Grow
by Abhinab Dasgupta
HCA Healthcare (HCA), ADMA Biologics (ADMA) and Exelixis (EXEL) are three medical stocks that you can look into as the sector continues to sustain its end-of-the-year momentum.
Is HCA (HCA) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), HCA (HCA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
HCA Healthcare, Inc. (HCA) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
HCA (HCA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
3 Sector ETFs & Stocks to Bet on Superb January Jobs Data
by Sanghamitra Saha
The U.S. economy added 353,000 for the month, much better than the Dow Jones estimate for 185,000 (as quoted on CNBC).
Inspire Medical (INSP) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Inspire Medical's (INSP) U.S. region witnesses strong revenue growth in the fourth quarter.
Why HCA Healthcare (HCA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
4 Top Stocks to Buy for Attractive Earnings Growth
by Tirthankar Chakraborty
Invest in stocks such as HCA Healthcare (HCA), Powell Industries (POWL), Axos Financial (AX), and Eagle Materials (EXP) for solid earnings growth.
HCA Healthcare (HCA) Is Up 9.17% in One Week: What You Should Know
by Zacks Equity Research
Does HCA Healthcare (HCA) have what it takes to be a top stock pick for momentum investors? Let's find out.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Buyback Bonanza: 3 Buy-Rated Companies Scooping Up Shares
by Derek Lewis
A common way that companies amplify shareholder value is through implementing share buybacks. And recently, these three companies have authorized precisely that.
Ensign Group (ENSG) Q4 Earnings Beat, Stock Up 5%
by Zacks Equity Research
Ensign Group's (ENSG) fourth-quarter results were aided by improved same-store occupancy and an increase in rental revenues. Management expects 2024 adjusted EPS within $5.29-$5.47.
If You Invested $1000 in HCA Healthcare 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Surmodics (SRDX) Q1 Earnings Top Estimates, Revises FY24 View
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust segmental revenues.
Best Momentum Stocks to Buy for February 2nd
by Zacks Equity Research
BK, HCA and HOOK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 2, 2023.
New Strong Buy Stocks for February 2nd
by Zacks Equity Research
USM, BK, KOF, HCA and AX have been added to the Zacks Rank #1 (Strong Buy) List on February 2, 2023.
3 Value Stocks to Buy After Beating Q4 Earnings Expectations
by Shaun Pruitt
Stronger-than-expected Q4 earnings on Tuesday helped rectify the notion that these stocks are undervalued making now an ideal time to buy.
Top Research Reports for Abbott, T-Mobile & Booking
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), T-Mobile US, Inc. (TMUS) Booking Holdings Inc. (BKNG).